Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TKMR Maxim Maintains Buy On Tekmira Pharmaceuticals Following 2Q14 Results
http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-tekmira-pharmaceuticals-following-2q14-results/
Maxim Maintains Buy On Tekmira Pharmaceuticals Following 2Q14 Results
http://www.smarteranalyst.com/2014/08/14/maxim-maintains-buy-on-tekmira-pharmaceuticals-following-2q14-results/
$DE Deere & Company: We Continue To See Downside To The Stock, Says William Blair http://www.smarteranalyst.com/2014/08/14/deere-company-we-continue-to-see-downside-to-the-stock-says-william-blair/
Deere & Company: We Continue To See Downside To The Stock, Says William Blair http://www.smarteranalyst.com/2014/08/14/deere-company-we-continue-to-see-downside-to-the-stock-says-william-blair/
$BONE William Blair Maintains Outperform On Bacterin Following Solid 2Q14 Results http://www.smarteranalyst.com/2014/08/14/william-blair-maintains-outperform-on-bacterin-following-solid-2q14-results/
$SPLK Wedbush Reiterates Outperform On Splunk Following “SplunkLive” Marketing Event http://www.smarteranalyst.com/2014/08/14/wedbush-reiterates-outperform-on-splunk-following-splunklive-marketing-event/
$MYGN William Blair Maintains Outperform On Myriad Genetics Following Fiscal 4Q14 Results http://www.smarteranalyst.com/2014/08/14/william-blair-maintains-outperform-on-myriad-genetics-following-fiscal-4q14-results/
$JDSU JDS Uniphase: The Risk/Reward Equation Remains Favorable, Says William Blair http://www.smarteranalyst.com/2014/08/14/jds-uniphase-the-riskreward-equation-remains-favorable-says-william-blair/
Cree: We Expect The Stock To Be Volatile On Weak LED Chip Volumes, Says Wedbush http://www.smarteranalyst.com/2014/08/14/cree-we-expect-the-stock-to-be-volatile-on-weak-led-chip-volumes-says-wedbush/
$AMZN Amazon: Third-Party Growth Is Evidence Of Payback To Long-Term Investors, Says William Blair http://www.smarteranalyst.com/2014/08/14/amazon-third-party-growth-is-evidence-of-payback-to-long-term-investors-says-william-blair/
$AMZN Amazon: Third-Party Growth Is Evidence Of Payback To Long-Term Investors, Says William Blair http://www.smarteranalyst.com/2014/08/14/amazon-third-party-growth-is-evidence-of-payback-to-long-term-investors-says-william-blair/
$AMZN Amazon: Third-Party Growth Is Evidence Of Payback To Long-Term Investors, Says William Blair http://www.smarteranalyst.com/2014/08/14/amazon-third-party-growth-is-evidence-of-payback-to-long-term-investors-says-william-blair/
$AMZN Amazon: Third-Party Growth Is Evidence Of Payback To Long-Term Investors, Says William Blair http://www.smarteranalyst.com/2014/08/14/amazon-third-party-growth-is-evidence-of-payback-to-long-term-investors-says-william-blair/
Amazon: Third-Party Growth Is Evidence Of Payback To Long-Term Investors, Says William Blair http://www.smarteranalyst.com/2014/08/14/amazon-third-party-growth-is-evidence-of-payback-to-long-term-investors-says-william-blair/
$IDRA Cowen Maintains Outperform On Idera Following 2Q14 Results http://www.smarteranalyst.com/2014/08/13/cowen-maintains-outperform-on-idera-following-2q14-results/
$IDRA Cowen Maintains Outperform On Idera Following 2Q14 Results http://www.smarteranalyst.com/2014/08/13/cowen-maintains-outperform-on-idera-following-2q14-results/
$EPZM Cowen Maintains Buy On Epizyme Following 2Q14 Results And Corporate Update http://www.smarteranalyst.com/2014/08/13/cowen-maintains-buy-on-epizyme-following-2q14-results-and-corporate-update/
$EPZM Cowen Maintains Buy On Epizyme Following 2Q14 Results And Corporate Update http://www.smarteranalyst.com/2014/08/13/cowen-maintains-buy-on-epizyme-following-2q14-results-and-corporate-update/
$EPZM Cowen Maintains Buy On Epizyme Following 2Q14 Results And Corporate Update http://www.smarteranalyst.com/2014/08/13/cowen-maintains-buy-on-epizyme-following-2q14-results-and-corporate-update/
$STEM Maxim Maintains Buy On Stem Cells Following 2Q14; Sees %312 Upside For The Stock http://www.smarteranalyst.com/2014/08/13/maxim-maintains-buy-on-stem-cells-following-2q14-sees-12-upside-for-the-stock/
$STEM Maxim Maintains Buy On Stem Cells Following 2Q14; Sees %312 Upside For The Stock http://www.smarteranalyst.com/2014/08/13/maxim-maintains-buy-on-stem-cells-following-2q14-sees-12-upside-for-the-stock/
$SGYP Synergy Pharmaceuticals: Patient Investors Will Be Rewarded At Current Prices, Says Roth Capital http://www.smarteranalyst.com/2014/08/13/synergy-pharmaceuticals-patient-investors-will-be-rewarded-at-current-prices-says-roth-capital/
$SGYP Synergy Pharmaceuticals: Patient Investors Will Be Rewarded At Current Prices, Says Roth Capital http://www.smarteranalyst.com/2014/08/13/synergy-pharmaceuticals-patient-investors-will-be-rewarded-at-current-prices-says-roth-capital/
$CPRX Roth Capital’s Scott Henry Maintains Buy On Catalyst Pharmaceutical Following Firdapse Phase 3 Completion http://www.smarteranalyst.com/2014/08/13/catalyst-pharmaceutical-partners-inc-cprx/
APP Roth Capital Reiterates Buy On American Apparel Following Preliminary 2Q14 Results http://www.smarteranalyst.com/2014/08/13/roth-capital-reiterates-buy-on-american-apparel-following-preliminary-2q14-results/
$APP Roth Capital Reiterates Buy On American Apparel Following Preliminary 2Q14 Results http://www.smarteranalyst.com/2014/08/13/roth-capital-reiterates-buy-on-american-apparel-following-preliminary-2q14-results/
$SOL ReneSola’s Stock May Be Challenged In The Near Term, Says Roth Capital http://www.smarteranalyst.com/2014/08/13/renesolas-stock-may-be-challenged-in-the-near-term-says-roth-capital/
Cantor Maintains Buy On Synergy Following 2Q14 Results; Sees Temporary Financing Overhang http://www.smarteranalyst.com/2014/08/13/cantor-maintains-buy-on-synergy-following-2q14-results-sees-temporary-financing-overhang/
$SGYP Cantor Maintains Buy On Synergy Following 2Q14 Results; Sees Temporary Financing Overhang http://www.smarteranalyst.com/2014/08/13/cantor-maintains-buy-on-synergy-following-2q14-results-sees-temporary-financing-overhang/
$DVAX Dynavax Is Substantially Undervalued For The Heplisav Opportunity Alone, Says Cowen
http://www.smarteranalyst.com/2014/08/08/dynavax-is-substantially-undervalued-for-the-heplisav-opportunity-alone-says-cowen/
$SRPT Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
$SRPT Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
$SRPT Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
$SRPT Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
$SRPT Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
Cowen Maintains Outperform On Sarepta As It’s Gearing Up For A Busy 2H14 http://www.smarteranalyst.com/2014/08/08/cowen-maintains-outperform-on-sarepta-as-its-gearing-up-for-a-busy-2h14/
We Expect Neurocrine To Outperform The Market As Its Pipeline Advances, Says Cowen http://www.smarteranalyst.com/2014/08/08/we-expect-neurocrine-to-outperform-the-market-as-its-pipeline-advances-says-cowen/
$AEZS H.C. Wainwright Reiterates Buy On Aeterna Zentaris Following 2Q14 Business Update http://bit.ly/1q1hyFI
Roth Capital Upgrades PowerSecure To A Buy Following Release 2Q14 Results http://www.smarteranalyst.com/2014/08/08/roth-capital-upgrades-powersecure-to-a-buy-following-release-2q14-results/
Orbitz Worldwide: We Opt To Stay On The Sidelines, Says Cantor Fitzgerald
http://www.smarteranalyst.com/2014/08/08/orbitz-worldwide-we-opt-to-stay-on-the-sidelines-says-cantor-fitzgerald/